Despite clear drug targets and well-understood biology, drug development efforts have not resulted in effective therapies for severe muscle diseases, largely due to the inability to deliver enough medicine to muscles while minimizing exposure to other tissues. Through our revolutionary FORCETM platform, we aim to bring the first disease-modifying treatments to patients and families affected by these diseases.
We are working closely with the patient community to understand the experience of living with a rare muscle disease. You can view our fireside chat with the FSHD community and learn more about one patient’s experience with DM1 below.
‘I’m not alone in this’: One patient’s journey with DM1
Growing up, Joachim Boekelmann says, myotonic dystrophy “was always in my background, and in the back of my head.”
His father was diagnosed in his 40s with the inherited muscle-wasting disease, meaning that Joachim and his sister each had a 50-50 chance of carrying it. Joachim took a genetic test and learned that he was a carrier. His sister was later diagnosed, too.
At the time, Joachim had no symptoms. Doctors said they would begin to appear at some point. Exactly when was anyone’s guess.
“In a way, it was a shock, but not really,” recalls Joachim, now 51. “It confirmed what I had thought was possible.”
Myotonic dystrophy type 1, or DM1, causes progressive muscle weakness and myotonia, or difficulty relaxing muscles, along with a wide variety of other symptoms affecting everything from breathing and speech to digestion and vision. The nature, severity and onset of symptoms can vary significantly, even among family members. There is no cure for DM1, which affects approximately one out of every 2,300 people worldwide.
For Joachim, the symptoms began in his early 30s: first myotonia, followed by weakness in his hands and difficulty swallowing. His shoulder blades would protrude when he lifted him arms.
In 2005, at age 37, he was officially diagnosed with DM1.
I am very optimistic that an effective treatment for DM1 will be found.
“It took me a long time to accept the disease,” says Joachim, who works as an attorney at a reinsurance company and lives with his wife and two children, ages 20 and 14, in a ranch-style house with no stairs in Princeton, NJ. “I’m trying to do as many things as I can. My wife might ask me if I need help with opening a jar or a yogurt cup, and often I’ll say no. I don’t always want to admit that I cannot do a certain thing.”
Indeed, Joachim’s disease can make everyday activities a challenge. He walks slowly, and sometimes trips and falls. His speech is nasally, which can occasionally make him hard to understand. A German native who has always enjoyed traveling, Joachim can no longer lift a moderately heavy suitcase, and sometimes has trouble opening the car door. A weak grip has made one of his favorite hobbies – building model trains – more taxing.
Joachim says his sister’s symptoms are even more severe. And he remembers the physical and emotional toll that DM1 took on his father; by the time he died at age 75, he couldn’t walk, dress or feed himself.
Joachim also knows there is a chance that his children might carry the disease, too. They have yet to be tested.
“That’s the scary part – what lies ahead?” Joachim says. “I saw my dad, how he deteriorated. I have seen how my sister has deteriorated over the last couple of years. What lies ahead five or ten years from now?”
Despite the uncertainty, Joachim draws strength from his family and inspiration from other patients living with DM1 whom he has met through Myotonic, the world’s largest patient organization focused solely on myotonic dystrophy. “You get the sense, I’m not alone in this,” he says of events like a Myotonic conference that he attended in 2014.
Joachim says he does not want to be defined by DM1. He has tried to remain as active and independent as possible. Through all of the daily challenges, his support network and personal faith have helped him persevere.
Meanwhile, he believes that finding a cure is a matter of when – not if.
“Given the research developments of the past few years and the number of drug makers that are actively involved in the research,” Joachim says, “I am very optimistic that an effective treatment for DM1 will be found.”